Abstract
Dermatologic TherapyVolume 35, Issue 3 e15277 LETTER Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities Filip Rob, Corresponding Author Filip Rob filip.rob@bulovka.cz Department of Dermatovenereology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech Republic Correspondence Filip Rob, Department of Dermatovenereology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague. Email: filip.rob@bulovka.czSearch for more papers by this authorHanuš Rozsypal, Hanuš Rozsypal Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech RepublicSearch for more papers by this author Filip Rob, Corresponding Author Filip Rob filip.rob@bulovka.cz Department of Dermatovenereology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech Republic Correspondence Filip Rob, Department of Dermatovenereology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague. Email: filip.rob@bulovka.czSearch for more papers by this authorHanuš Rozsypal, Hanuš Rozsypal Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech RepublicSearch for more papers by this author First published: 19 December 2021 https://doi.org/10.1111/dth.15277Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume35, Issue3March 2022e15277 RelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
